BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 27830376)

  • 1. Clinical effectiveness of itraconazole as antifungal prophylaxis in AML patients undergoing intensive chemotherapy in the modern era.
    Keighley CL; Manii P; Larsen SR; van Hal S
    Eur J Clin Microbiol Infect Dis; 2017 Feb; 36(2):213-217. PubMed ID: 27830376
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Itraconazole vs. posaconazole for antifungal prophylaxis in patients with acute myeloid leukemia undergoing intensive chemotherapy: A retrospective study.
    Copley MS; Waldron M; Athans V; Welch SC; Brizendine KD; Cober E; Siebenaller C
    Int J Antimicrob Agents; 2020 Mar; 55(3):105886. PubMed ID: 31926286
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacoeconomic evaluation of fluconazole, posaconazole and voriconazole for antifungal prophylaxis in patients with acute myeloid leukaemia undergoing first consolidation chemotherapy.
    Heng SC; Slavin MA; Al-Badriyeh D; Kirsa S; Seymour JF; Grigg A; Thursky K; Bajel A; Nation RL; Kong DC
    J Antimicrob Chemother; 2013 Jul; 68(7):1669-78. PubMed ID: 23485723
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-benefit Analysis of Posaconazole Versus Fluconazole or Itraconazole as a Primary Antifungal Prophylaxis in High-risk Hematologic Patients: A Propensity Score-matched Analysis.
    Cho SY; Lee DG; Choi JK; Lee HJ; Kim SH; Park SH; Choi SM; Choi JH; Yoo JH; Kim YJ; Kim HJ; Min WS; Back H; Kang S; Lee EK
    Clin Ther; 2015 Sep; 37(9):2019-27. PubMed ID: 26188835
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the practice of antifungal prophylaxis use in patients with newly diagnosed acute myeloid leukemia: results from the SEIFEM 2010-B registry.
    Pagano L; Caira M; Candoni A; Aversa F; Castagnola C; Caramatti C; Cattaneo C; Delia M; De Paolis MR; Di Blasi R; Di Caprio L; Fanci R; Garzia M; Martino B; Melillo L; Mitra ME; Nadali G; Nosari A; Picardi M; Potenza L; Salutari P; Trecarichi EM; Tumbarello M; Verga L; Vianelli N; Busca A;
    Clin Infect Dis; 2012 Dec; 55(11):1515-21. PubMed ID: 22955439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Azole-based chemoprophylaxis of invasive fungal infections in paediatric patients with acute leukaemia: an internal audit.
    Yunus S; Pieper S; Kolve H; Goletz G; Jürgens H; Groll AH
    J Antimicrob Chemother; 2014 Mar; 69(3):815-20. PubMed ID: 24198097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary prophylaxis of invasive fungal infections with posaconazole or itraconazole in patients with acute myeloid leukaemia or high-risk myelodysplastic syndromes undergoing intensive cytotoxic chemotherapy: A real-world comparison.
    Tormo M; Pérez-Martínez A; Calabuig M; Hernández-Boluda JC; Amat P; Navarro D; Solano C
    Mycoses; 2018 Mar; 61(3):206-212. PubMed ID: 29125660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The cost-utility analysis of antifungal prophylaxis for invasive fungal infections in acute myeloid leukaemia patients receiving chemotherapy: a study from a middle-income country.
    Pungprasert T; Dhirachaikulpanich D; Phutthasakda W; Tantai N; Maneeon S; Nganthavee V; Atipas K; Tanpong S; Krithin S; Tanglitanon S; Jutidamrongphan W; Chayakulkeeree M; Srinonprasert V; Phikulsod P
    J Hosp Infect; 2024 Mar; 145():118-128. PubMed ID: 38219835
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia.
    Cornely OA; Maertens J; Winston DJ; Perfect J; Ullmann AJ; Walsh TJ; Helfgott D; Holowiecki J; Stockelberg D; Goh YT; Petrini M; Hardalo C; Suresh R; Angulo-Gonzalez D
    N Engl J Med; 2007 Jan; 356(4):348-59. PubMed ID: 17251531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The incidence of invasive fungal infections in neutropenic patients with acute leukemia and myelodysplastic syndromes receiving primary antifungal prophylaxis with voriconazole.
    Barreto JN; Beach CL; Wolf RC; Merten JA; Tosh PK; Wilson JW; Hogan WJ; Litzow MR
    Am J Hematol; 2013 Apr; 88(4):283-8. PubMed ID: 23460251
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liposomal amphotericin B versus the combination of fluconazole and itraconazole as prophylaxis for invasive fungal infections during induction chemotherapy for patients with acute myelogenous leukemia and myelodysplastic syndrome.
    Mattiuzzi GN; Estey E; Raad I; Giles F; Cortes J; Shen Y; Kontoyiannis D; Koller C; Munsell M; Beran M; Kantarjian H
    Cancer; 2003 Jan; 97(2):450-6. PubMed ID: 12518369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative clinical effectiveness of prophylactic voriconazole/posaconazole to fluconazole/itraconazole in patients with acute myeloid leukemia/myelodysplastic syndrome undergoing cytotoxic chemotherapy over a 12-year period.
    Ananda-Rajah MR; Grigg A; Downey MT; Bajel A; Spelman T; Cheng A; Thursky KT; Vincent J; Slavin MA
    Haematologica; 2012 Mar; 97(3):459-63. PubMed ID: 22058198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical effectiveness of posaconazole prophylaxis in patients with acute myelogenous leukaemia (AML): a 6 year experience of the Cologne AML cohort.
    Vehreschild JJ; Rüping MJ; Wisplinghoff H; Farowski F; Steinbach A; Sims R; Stollorz A; Kreuzer KA; Hallek M; Bangard C; Cornely OA
    J Antimicrob Chemother; 2010 Jul; 65(7):1466-71. PubMed ID: 20410061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of intravenous voriconazole and intravenous itraconazole for antifungal prophylaxis in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome.
    Mattiuzzi GN; Cortes J; Alvarado G; Verstovsek S; Koller C; Pierce S; Blamble D; Faderl S; Xiao L; Hernandez M; Kantarjian H
    Support Care Cancer; 2011 Jan; 19(1):19-26. PubMed ID: 19956980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A cohort study on breakthrough invasive fungal infections in high-risk patients receiving antifungal prophylaxis.
    Biehl LM; Vehreschild JJ; Liss B; Franke B; Markiefka B; Persigehl T; Bücker V; Wisplinghoff H; Scheid C; Cornely OA; Vehreschild MJ
    J Antimicrob Chemother; 2016 Sep; 71(9):2634-41. PubMed ID: 27317443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacoeconomic evaluation of voriconazole versus posaconazole for antifungal prophylaxis in acute myeloid leukaemia.
    Al-Badriyeh D; Slavin M; Liew D; Thursky K; Downey M; Grigg A; Bajel A; Stewart K; Kong DC
    J Antimicrob Chemother; 2010 May; 65(5):1052-61. PubMed ID: 20237074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antifungal prophylaxis with posaconazole vs. fluconazole or itraconazole in pediatric patients with neutropenia.
    Döring M; Eikemeier M; Cabanillas Stanchi KM; Hartmann U; Ebinger M; Schwarze CP; Schulz A; Handgretinger R; Müller I
    Eur J Clin Microbiol Infect Dis; 2015 Jun; 34(6):1189-200. PubMed ID: 25680318
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SEIFEM 2010-E: economic evaluation of posaconazole for antifungal prophylaxis in patients with acute myeloid leukemia receiving induction chemotherapy.
    Busca A; Lessi F; Verga L; Candoni A; Cattaneo C; Cesaro S; Dragonetti G; Delia M; De Luca A; Guglielmi G; Tumbarello M; Martino G; Nadali G; Fanci R; Picardi M; Potenza L; Nosari A; Aversa F; Pagano L;
    Leuk Lymphoma; 2017 Dec; 58(12):2859-2864. PubMed ID: 28508692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-Lasting Protective Effect of Posaconazole Prophylaxis in Patients with Acute Myeloid Leukemia Receiving Allogeneic Hematopoietic Stem Cell Transplantation.
    Busca A; Candoni A; Audisio E; Passera R; Bruno B; Monaco F; Mordini N; Vacca A; Delia M; Aversa F; Pagano L
    Biol Blood Marrow Transplant; 2016 Dec; 22(12):2214-2219. PubMed ID: 27667012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Posaconazole for primary antifungal prophylaxis in patients with acute myeloid leukaemia or myelodysplastic syndrome during remission induction chemotherapy: a single-centre retrospective study in Korea and clinical considerations.
    Cho SY; Lee DG; Choi SM; Choi JK; Lee HJ; Kim SH; Park SH; Choi JH; Yoo JH; Kim YJ; Kim HJ; Min WS
    Mycoses; 2015 Sep; 58(9):565-71. PubMed ID: 26214656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.